Veradermics Quarterly Income Statement
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
130.90+4.27 (+3.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veradermics revenue and earnings
Veradermics reported a net loss of $23.5 million. Diluted earnings per share came in at -$0.58.
Summary generated from market data by MetaCap's automated system. Methodology
Veradermics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q2 20252025-06-30 | Q1 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 29.55M | 29.86M | 16.07M | 12.91M |
| Research & Development | 18.61M | 20.93M | 14.33M | 11.45M |
| Operating Income | -29.55M | -29.86M | -16.07M | -12.91M |
| Other Income (Expense) | 6.05M | 2.63M | 428.00K | 515.00K |
| Pretax Income | -23.50M | -27.23M | -15.64M | -12.40M |
| Income Tax | 0 | 0 | 0 | 0 |
| Net Income | -23.50M | -27.23M | -15.64M | -12.40M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.58 | -1.32 | -24.19 | -19.79 |
| EPS (Diluted) | -0.58 | -1.32 | -24.19 | -19.79 |
| Shares Outstanding (Basic) | 40.44M | 22.70M | 744.64K | 736.93K |
| Shares Outstanding (Diluted) | 40.44M | 22.70M | 744.64K | 736.93K |
This table shows 4 quarterly periods of Veradermics's income statement, from Q2 2026 back to Q1 2025, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MANE's reporting calendar. What is a income statement?